The Nasdaq-listed company said the divestiture follows unanimous board approval and marks a strategic pivot toward the Canton Network ecosystem, asset tokenization and compliant financial infrastructure services.
Canton Strategic Holdings said it has completed the sale of its biotech research and development unit, Gravitas Life Sciences, to Gravitas Collective Corp, with settlement finalized on July 17, 2026, after unanimous board approval. The Nasdaq-listed company said the divestiture is part of a broader strategic shift away from biotech and toward the Canton Network ecosystem, asset tokenization, financial digitization and compliant financial infrastructure services.